GoodRx (NASDAQ:GDRX) Trading Down 8.4% on Analyst Downgrade

GoodRx Holdings, Inc. (NASDAQ:GDRXGet Free Report) was down 8.4% on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.16 and last traded at $4.17. Approximately 959,968 shares changed hands during trading, a decline of 25% from the average daily volume of 1,288,451 shares. The stock had previously closed at $4.55.

GDRX has been the topic of several other research reports. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target for the company. Morgan Stanley dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Finally, Barclays lowered their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.38.

Check Out Our Latest Report on GoodRx

Institutional Investors Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the company. Fortem Financial Group LLC boosted its holdings in shares of GoodRx by 7.2% in the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after acquiring an additional 7,996 shares during the period. JPMorgan Chase & Co. lifted its holdings in GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after purchasing an additional 18,997 shares in the last quarter. Franklin Resources Inc. bought a new position in GoodRx in the 3rd quarter worth about $5,675,000. Sanctuary Advisors LLC purchased a new position in GoodRx during the 3rd quarter valued at about $85,000. Finally, Barclays PLC increased its position in shares of GoodRx by 1,316.1% during the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

The business’s fifty day moving average price is $4.68 and its 200-day moving average price is $6.53. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market capitalization of $1.61 billion, a PE ratio of -140.67, a P/E/G ratio of 3.43 and a beta of 1.27.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Featured Articles

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.